Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer

References

• American Cancer Society. Cancer Facts and Figures 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed January 2016
   Google Scholar
• Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703
   PubMed Web of Science ®Google Scholar
• Ko AH. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. J Clin Oncol 2015;33:1779-86
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Sutton A, Ades AE, Cooper N, et al. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008;26:753-67
   PubMed Web of Science ®Google Scholar
• Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Chen Q, Ayer T, et al. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol 2015;33:1112-18
   PubMed Web of Science ®Google Scholar
• Gharaibeh M, Bootman JL, McBride A, Martin J, Abraham I. Economic evaluations of first-line chemotherapy regimens for pancreatic cancer: a critical review. Pharmacoeconomics 2016; [Epub ahead of print: DOI: 10.1007/s40273-016-0452-6] Review
   PubMed Web of Science ®Google Scholar
• Gharaibeh M, McBride A, Bootman JL, et al. Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer. Br J Cancer 2015;112:1301-5
   PubMed Web of Science ®Google Scholar
• Gray A, Clarke P, Wolstenholme J, et al. Applied methods of cost-effectiveness analysis in health care. Oxford, UK: Oxford University Press; 2011. p 61-82
   Google Scholar
• Gharaibeh M, Patel H, McBride A, et al. Weibull and exponential proportional hazard modelling for optimizing economic evaluations of cancer treatments: FOLFIRINOX (FFX) vs gemcitabine (GEM) in metastatic pancreas cancer (mPC). J Clin Oncol 2016:34(suppl; abstr e15704)
   Google Scholar
• US Department of Labor. Bureau of Labor Statistics Consumer Price Index: All urban consumers–US medical care services. http://www.bls.gov/cpi/. Accessed January 2016
   Google Scholar
• Red Book Online [subscription database online]. Greenwood Village, CO: Truven Health Analytics, Inc. Updated periodically.
   Google Scholar
• Centers for Disease Control and Prevention. 2015 Medicare physician fee schedule. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/Physician FeeSched/index.html?redirect_/physicianfeesched. Accessed January 2016
   Google Scholar
• Dranitsaris G, Maroun J, Shah A. Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea. Can J Gastroenterol 2005;19:83-7
   PubMed Web of Science ®Google Scholar
• Liou SY, Stephens JM, Carpiuc KT, et al. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig 2007;27:381-96
   PubMed Web of Science ®Google Scholar
• Cantor SB, Hudson DV Jr, Lichtiger B, et al. Costs of blood transfusion: a process-flow analysis. J Clin Oncol 1998;16:2364-70
   PubMed Web of Science ®Google Scholar
• Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. Exp Ther Med 2011;2:859-66
   PubMed Web of Science ®Google Scholar
• Wang SJ, Fuller CD, Choi M, et al. A cost-effectiveness analysis of adjuvant chemoradiotherapy for resected gastric cancer. Gastrointest Cancer Res 2008;2:57-63
   PubMedGoogle Scholar
• Tam VC, Ko YJ, Mittmann N, et al. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Curr Oncol 2013;20:e90-e106
   PubMed Web of Science ®Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York, NY: Oxford University Press; 2011. p 77-120
   Google Scholar
• Romanus D, Kindler HL, Archer L, et al. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 2012;43:205-17
   PubMed Web of Science ®Google Scholar
• Cooper NJ, Abrams KR, Sutton AJ, et al. A Bayesian approach to Markov modelling in cost-effectiveness analyses: application to taxane use in advanced breast cancer. J Roy Statist Soc A 2003;166:389-405
   Web of Science ®Google Scholar
• Abraham I, Harrington AR, Bootman JL. The QALY controversy in the United States. Invited presentation at the EU Special Conference ??Health Outcomes in Europe: the QALY controversy. New European Guidelines in Cost-Effectiveness Assessment??. Brussels, Belgium 2013. Available at: http://www.echoutcome.eu/images/stories/Abraham_QALY_Controversy_in_US.pdf. Accessed: 25 January 2016.
   Google Scholar
• Holtgrave DR, Qualls NL. Threshold analysis and programs for prevention of HIV infection. Med Decis Making 1995;15:311-17
   PubMed Web of Science ®Google Scholar
• Schulman KA, Lynn LA, Glick HA, et al. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 1991;114:798-802
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011;103:117-28
   PubMed Web of Science ®Google Scholar
• Abraham I, McBride A, MacDonald K. Arguing (about) the value of cancer care. J Natl Compr Canc Netw 2016;14:1487-9
   PubMed Web of Science ®Google Scholar
• Tangka FK, Trogdon JG, Richardson LC, et al. Cancer treatment cost in the United States: has the burden shifted over time? Cancer 2010;116:3477-84
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Cancer Trends Progress Report–2011/2012 Update. Available at: http://progressreport.cancer.gov. Accessed: January 2016.
   Google Scholar
• Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 2015;33:2563-77
   PubMed Web of Science ®Google Scholar
• Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015;107;pii:dju413
   PubMedGoogle Scholar
• Bekaii-Saab T, Goldberg R. Therapeutic advances in pancreatic cancer: miles to go before we sleep. J Natl Cancer Inst 2015;107;pii:dju439
   PubMedGoogle Scholar
• Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013;31:23-9
   PubMed Web of Science ®Google Scholar
• Mills EJ, Ghement I, O’Regan C, et al. Estimating the power of indirect comparisons: a simulation study. PLoS One 2011;6:e16237
   PubMed Web of Science ®Google Scholar